Body fluid management as a treatment for obstructive sleep apnea: a new possibility for sodium-glucose cotransporter 2 inhibitors
- PMID: 39706888
- DOI: 10.1038/s41440-024-02063-1
Body fluid management as a treatment for obstructive sleep apnea: a new possibility for sodium-glucose cotransporter 2 inhibitors
Keywords: Fluid shift; Heart failure; Novel therapy; Sleep-disordered breathing; Tofogliflozin.
Conflict of interest statement
Compliance with ethical standards. Conflict of interest: The authors declare no competing interests.
Comment on
-
Tofogliflozin reduces sleep apnea severity in patients with type 2 diabetes mellitus and heart failure: a prospective study.Hypertens Res. 2025 Jan;48(1):388-397. doi: 10.1038/s41440-024-01982-3. Epub 2024 Nov 12. Hypertens Res. 2025. PMID: 39528646
References
-
- Ishiwata S., Kasai T., Sato A., Suda S, Matsumoto H. et al. Tofogliflozin reduces sleep apnea severity in patients with type 2 diabetes mellitus and heart failure: a prospective study. Hypertens Res. 2025;48:388–97.
-
- Silva BC, Santos RSS, Drager LF, Coelho FM, Elias RM. Impact of compression stockings vs. continuous positive airway pressure on overnight fluid shift and obstructive sleep apnea among patients on hemodialysis. Front Med. 2017;4:57. - DOI